首页> 外文OA文献 >New complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture
【2h】

New complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture

机译:用于在无血清悬浮培养中生产E1缺失的腺病毒载体的新型补体细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

E1-deleted adenovirus vectors (AdV) are important gene transfer vehicles for gene therapy and vaccination. Amplification of AdV must take place in cells that express the adenovirus E1A and E1B genes. Sequence homology between AdV and the E1 genes integrated within the complementing cells should be minimal to reduce the odds of generating replication-competent adenovirus (RCA). The present study describes the establishment of AdV complementing cells constructed by stable transfection of the minimal E1A and E1B genes into human lung carcinoma (A549). Because some transgene products can be cytotoxic, the cells were engineered to stably express the repressor of the cumate-switch (CymR) to silence transgene transcription during vector growth. For regulatory compliance and to facilitate the scale-up, the resulting complementing cells (SF-BMAdR) were adapted to serum-free suspension culture. The best clone of SF-BMAdR produced AdV carrying an innocuous transgene to the same level as 293 cells, but titers were better for AdV carrying transgene for a cytotoxic product. Elevated titers were maintained for at least two months in suspension culture in the absence of selective agent and the cells did not produce RCA. Because of their advantageous properties, SF-BMAdR cells should become an important tool for developing large-scale production processes of AdV for research and clinical applications.
机译:缺失E1的腺病毒载体(AdV)是用于基因治疗和疫苗接种的重要基因转移载体。 AdV的扩增必须在表达腺病毒E1A和E1B基因的细胞中进行。 AdV和整合在补体细胞中的E1基因之间的序列同源性应最小,以降低产生复制型腺病毒(RCA)的几率。本研究描述了通过将最小的E1A和E1B基因稳定转染到人肺癌(A549)中而构建的AdV互补细胞的建立。由于某些转基因产物可能具有细胞毒性,因此对细胞进行了改造,使其能够稳定表达cumate-switch(CymR)的阻遏物,从而在载体生长过程中沉默转基因转录。为了符合法规要求并促进放大,将所得的补体细胞(SF-BMAdR)进行无血清悬浮培养。 SF-BMAdR的最佳克隆可产生带有无害转基因的AdV,其水平与293细胞相同,但对于带有细胞毒性产品的带有转基因的AdV,滴度更好。在没有选择剂的情况下,在悬浮培养中将升高的滴度维持至少两个月,并且细胞不产生RCA。由于其有利的特性,SF-BMAdR细胞应成为开发用于研究和临床应用的AdV大规模生产工艺的重要工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号